Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Published
January 09, 2021
Journal
Cancer treatment reviews
PICOID
fae2f99f
DOI
Citations
46
Keywords
(177)Lu-DOTATATE, Lutetium-177 DOTATATE, Neuroendocrine tumor, Peptide receptor radionuclide therapy, Progression-free survival
Copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Patients/Population/Participants
adults with neuroendocrine tumors (NETs)
Intervention
peptide receptor radionuclide therapy (PRRT) re-treatment
Comparison
previous treatment with PRRT
Outcome
efficacy and safety outcomes
Abstract
P
I
C
O
This review and meta-analysis examined published evidence of peptide receptor radionuclide therapy (PRRT) re-treatment efficacy and safety in patients with advanced neuroendocrine tumors (NETs). Embase, MEDLINE, MEDLINE In-Progress, and Cochrane CENTRAL were searched (database inception-present) to identify evidence of efficacy and safety of PRRT re-treatment in adults with NETs previously treated with Of 567 studies screened, 13 reported re-treatment efficacy outcomes. In random-effects meta-analyses of Re-treatment with